Video
Christopher Mast, MD, vice president of clinical informatics at Epic, explains his outlook for the future in the field of oncology in light of the ongoing delays in cancer screenings rates.
Pharmacy Times interviewed Christopher Mast, MD, vice president of clinical informatics at Epic, on research demonstrating that despite cancer screening rates rebounding in 2021 from the low rates at the beginning of the pandemic, they were still lower than experts in the field had expected.
During the discussion, Mast addressed what pharmacists can do to address cancer screening rates and his outlook for the future of the field following the release of the results from the study.